|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.
|
27564568 |
2017 |
|
Acute lymphocytic leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
The frequencies of TPMT*2, TPMT A719G, NQO1*2 and CYP1A1*2 variants were examined in 100 patients with ALL and 106 healthy controls by allele specific PCR and/or PCR-RFLP methods using blood samples.
|
23065291 |
2013 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
The frequencies of TPMT*2, TPMT A719G, NQO1*2 and CYP1A1*2 variants were examined in 100 patients with ALL and 106 healthy controls by allele specific PCR and/or PCR-RFLP methods using blood samples.
|
23065291 |
2013 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
The frequencies of TPMT*2, TPMT A719G, NQO1*2 and CYP1A1*2 variants were examined in 100 patients with ALL and 106 healthy controls by allele specific PCR and/or PCR-RFLP methods using blood samples.
|
23065291 |
2013 |
|
Acute lymphocytic leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Five (8.6%) of 58 children with ALL had a polymorphic TPMT allele: 4 (3.4%) were heterozygous for TPMT*3A (G460A and A719G), and one (0.9%) was heterozygous for TPMT*3C (A719G).
|
21400026 |
2011 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Five (8.6%) of 58 children with ALL had a polymorphic TPMT allele: 4 (3.4%) were heterozygous for TPMT*3A (G460A and A719G), and one (0.9%) was heterozygous for TPMT*3C (A719G).
|
21400026 |
2011 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Five (8.6%) of 58 children with ALL had a polymorphic TPMT allele: 4 (3.4%) were heterozygous for TPMT*3A (G460A and A719G), and one (0.9%) was heterozygous for TPMT*3C (A719G).
|
21400026 |
2011 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
|
Acute lymphocytic leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.030 |
GeneticVariation
|
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
|
Thiopurine S methyltranferase deficiency
|
|
0.020 |
GeneticVariation
|
BEFREE |
Three main TPMT alleles: TPMT*2 (c.238G>C), TPMT*3A (c.460G>A, c.719A>G) and TPMT*3C (c.719A>G) account for 80-95 % of inherited TPMT deficiency in different populations in the world.
|
27307154 |
2016 |
|
Thiopurine S methyltranferase deficiency
|
|
0.020 |
GeneticVariation
|
BEFREE |
The mutant alleles TPMT*2 (238G>C), TPMT*3A (460G>A, 719A>G), TPMT*3B (460G>A), and TPMT*3C (719A>G) account for 80-95% of TPMT deficiency observed in Caucasian populations.
|
14967158 |
2004 |
|
Ulcerative Colitis
|
|
0.010 |
GeneticVariation
|
BEFREE |
ITPA(94C>A, IVS2+21A>C) and TPMT (238G>C, 460G>A, and 719A>G) genotypes were assessed in 262 IBD patients (159 females, 103 males; 67 patients with ulcerative colitis, 195 patients with Crohn's disease) treated with AZA and were correlated with the development of leukopenia and hepatotoxicity.
|
16431304 |
2006 |
|
Inflammatory Bowel Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
ITPA(94C>A, IVS2+21A>C) and TPMT (238G>C, 460G>A, and 719A>G) genotypes were assessed in 262 IBD patients (159 females, 103 males; 67 patients with ulcerative colitis, 195 patients with Crohn's disease) treated with AZA and were correlated with the development of leukopenia and hepatotoxicity.
|
16431304 |
2006 |
|
Leukopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
ITPA(94C>A, IVS2+21A>C) and TPMT (238G>C, 460G>A, and 719A>G) genotypes were assessed in 262 IBD patients (159 females, 103 males; 67 patients with ulcerative colitis, 195 patients with Crohn's disease) treated with AZA and were correlated with the development of leukopenia and hepatotoxicity.
|
16431304 |
2006 |
|
Crohn Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
ITPA(94C>A, IVS2+21A>C) and TPMT (238G>C, 460G>A, and 719A>G) genotypes were assessed in 262 IBD patients (159 females, 103 males; 67 patients with ulcerative colitis, 195 patients with Crohn's disease) treated with AZA and were correlated with the development of leukopenia and hepatotoxicity.
|
16431304 |
2006 |